Precigen
Yahoo Finance • 15 days ago
Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS
Precigen, Inc. (NASDAQ:PGEN) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 3, Precigen, Inc. (NASDAQ:PGEN) announced that it signed a credit facility agreement with total funds of up to $125 millio... Full story
Yahoo Finance • 27 days ago
Precigen announces up to $125M non-dilutive financing
* Precigen (NASDAQ:PGEN [https://seekingalpha.com/symbol/PGEN]) said on Wednesday that it has entered into a credit facility agreement [https://seekingalpha.com/pr/20218815-precigen-announces-up-to-125-million-non-dilutive-financing] wit... Full story
Yahoo Finance • last month
Citizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform Rating
Precigen Inc. (NASDAQ:PGEN) is one of the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 18, Citizens JMP raised the price target on Precigen Inc. (NASDAQ:PGEN) from $6 to $8, keeping its Outperform rating on the s... Full story
Yahoo Finance • last month
Unusual volume stocks in Friday's session
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/p... Full story
Yahoo Finance • last month
Unusual volume stocks in Thursday's session
Unusual volume stocks are being observed in Thursday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT THAR [https://www.chartmill.com/stock/quote/THAR/profile] 32.17% THARIMMUNE INC (NASDAQ:THAR... Full story
Yahoo Finance • last month
Oppenheimer maintains Outperform rating on Inovio stock amid FDA approval for competitor
Investing.com - Oppenheimer has reiterated an Outperform rating and $13.00 price target on Inovio Pharmaceuticals (NASDAQ:INO) following the FDA approval of a competing therapy for recurrent respiratory papillomatosis (RRP). According to I... Full story
Yahoo Finance • last month
Precigen files to sell 143.81M shares of common stock for holders
* Precigen (NASDAQ:PGEN [https://seekingalpha.com/symbol/PGEN]) filed to sell 143.81M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10324555] MORE ON PRECIGEN * Precigen: This Billion-Dollar Approval... Full story
Yahoo Finance • 2 months ago
Precigen surges on FDA approval for gene therapy
[FDA headquarters in Washington DC.] JHVEPhoto Shares of Precigen (NASDAQ:PGEN [https://seekingalpha.com/symbol/PGEN]) added ~34% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) approved its gene therapy candi... Full story
Yahoo Finance • 2 months ago
Precigen earnings missed, revenue topped estimates
Investing.com - Precigen (NASDAQ: PGEN) reported second quarter EPS of $-0.090, worse than the analyst estimate of $-0.083. Revenue for the quarter came in at $856K versus the consensus estimate of $666.67K. Precigen’s stock price closed... Full story
Yahoo Finance • 2 months ago
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year
Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company specializing in DNA-based immunotherapies, stands at a critical juncture as it approaches the submission of its Biologics License Application (BLA) for its lead candidate,... Full story
Yahoo Finance • 2 months ago
JMP analyst reiterates Market Outperform rating on Inovio stock
Investing.com - JMP Securities has reiterated its Market Outperform rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ:INO), according to a research note published Wednesday. The target represents significant upside from the... Full story
Yahoo Finance • 2 years ago
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
– First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP – – Designation based on positive Phase 1 clinical data that showed 50% of pati... Full story
Yahoo Finance • 3 years ago
13 High Growth Pharma Stocks that are Profitable
In this piece, we will take a look at 13 high growth pharma stocks that are profitable. For more stocks, head on over to 5 High Growth Pharma Stocks that are Profitable. One industry that has rapidly evolved with time and impacted million... Full story
Yahoo Finance • 3 years ago
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
– Company achieved significant progress for its clinical pipeline in 2022 – – Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase 1 dose escalation and expansion cohor... Full story
Yahoo Finance • 3 years ago
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
GERMANTOWN, Md., Jan. 4, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Compa... Full story
Yahoo Finance • 3 years ago
Precigen Reports Second Quarter and First Half 2022 Financial Results
– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo Clinic in Rochester, Minnesota activated as first expansion site of Phase 1b multice... Full story
